ENTITY
Venus Medtech (Hangzhou)

Venus Medtech (Hangzhou) (2500 HK)

111
Analysis
Health Care • China
Venus Medtech is a leading medical device company specializing in transcatheter structural heart valvular therapies. It develops and commercializes innovative solutions for all four heart valves (TAVR, TPVR, TMVR, TTVR) and interventional hypertension treatment. The company was founded in 2009 and is headquartered in Hangzhou, China.
more
bullish•Alphamab Co Ltd
•08 Dec 2019 13:19

ECM Weekly (8 Dec 2019) - OneConnect, JS Global, Renrui, Poly Property, Freee, Burger King India

Aequitas Research puts out a weekly update on the deals that have been covered by the team recently along with updates for upcoming IPOs. This...

Share
•01 Dec 2019 11:18

ECM Weekly (1 Dec 2019) - Venus Medtech, Alphamab, CMC REIT, XD, BAM

Aequitas Research puts out a weekly update on the deals that have been covered by the team recently along with updates for upcoming IPOs. It has...

Share
•27 Nov 2019 19:28

Venus Medtech IPO: Fairly Valued and More Room for Share Price to Grow

In our previous insight on Venus Medtech IPO Venus Medtech IPO: First Mover Advantage in Chinese TAVR Market to Support Growth , we discussed the...

Share
•26 Nov 2019 23:01

Venus Medtech IPO: Valuation Tempting at the Low-End

Venus MedTech (2500 HK) is a leading transcatheter heart valve medical device company in China. Venus has launched a Hong Kong IPO to raise up to...

Logo
683 Views
Share
•26 Nov 2019 15:25

Venus Medtech (启明医疗) IPO: Valuation Still OK at the High End

Venus Medtech launched book building today to raise up to USD 331 million to list in Hong Kong. The deal attracted five cornerstone investors who...

Logo
814 Views
Share
x